Next generation tyrosine kinase inhibitor ( TKI ) : afatinib . DB08916 is a recently introduced new tyrosine kinase inhibitor , approved by the USFDA on July 12 , 2013 . DB08916 is marketed under the trade name Gilotrif and developed by Boehringer Ingelheim GmbH . It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer ( NSCLC ) carrying P00533 exon 19 deletions or exon 21 ( L858R ) mutations . DB08916 is a covalent , irreversible inhibitor of epidermal growth factor receptor ( P00533 ) , human epidermal growth factor receptor 2 ( P04626 ) and Q15303 . Chemically afatinib is a 4-anilinoquinazoline derivative , having an acrylamide warhead . Gilotrif is the formulation of DB08916 di-meleate salt . Presently , afatinib has been approved in the USA , the European Union , Taiwan and Mexico . In this review , we have summarized the chemical characterization of afatinib , its synthesis , patent status , marketed formulation , available crystalline form and current clinical trials .